Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-breast feeding female ≥ 18 years old~* In remission from demonstrated overt HE~* Had ≥1 episode of overt HE associated with liver disease within the last 6 months~* MELD score of ≥ 19~* Has a close family member or other personal contact who is familiar with the subject's HE, can provide continuing oversight to the subject and is willing to be available to the subject during the conduct of the trial~Exclusion Criteria:~* HIV~* History of tuberculosis infection~* Chronic respiratory insufficiency~* Current infection and receiving antibiotics~* Renal insufficiency requiring dialysis~* Active spontaneous bacterial peritonitis infection~* Intestinal obstruction or has inflammatory bowel disease~* Active malignancy within the last 5 years~* Current GI bleeding or has had a GI hemorrhage within past 3 months~* Anemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): Rifaximin, oral, 550 mg BID, 6 months of treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral, 0 mg BID, 6 months of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).